Invivyd (IVVD)

Company Profile

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.

Company profile

Ticker

IVVD

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...

Former names

Adagio Therapeutics, Inc.

SEC CIK

0001832038

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

851403134

IVVD stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Departure of Directors or Certain Officers

6 Dec 22

$23.75 mm in equity / options / securities to be acquired, sold $23.75 mm, 1 investor

29 Nov 22

8-K

Invivyd Announces Partnership with Population Health Partners to Accelerate Clinical Development In Infectious Diseases Including COVID-19

10 Nov 22

Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

10 Nov 22

8-K

Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors

24 Oct 22

8-K

Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery

13 Oct 22

EFFECT

Notice of effectiveness

6 Oct 22

CORRESP

Correspondence with SEC

3 Oct 22

Latest ownership filings

View all

Financial summary

Financial statements Chart IVVD financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	278.15 mm	278.15 mm	278.15 mm	278.15 mm	278.15 mm	278.15 mm
Cash burn (monthly)	65.58 mm	16.68 mm	15.78 mm	23.58 mm	91.67 k	4.96 mm
Cash used (since last report)	267.37 mm	67.99 mm	64.33 mm	96.12 mm	373.74 k	20.22 mm
Cash remaining	10.78 mm	210.16 mm	213.83 mm	182.03 mm	277.78 mm	257.94 mm
Runway (months of cash)	0.2	12.6	13.6	7.7	3030.3	52.0

Beta Read what these cash burn values mean

Financial data from Invivyd earnings reports.

Institutional ownership, Q3 2022

IVVD institutional ownership history Ownership history

95.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	74	81	-8.6%
Opened positions	9	19	-52.6%
Closed positions	16	16	–
Increased positions	21	19	+10.5%
Reduced positions	19	22	-13.6%

13F shares	Current	Prev Q	Change
Total value	270.16 mm	321.23 mm	-15.9%
Total shares	103.64 mm	103.75 mm	-0.1%
Total puts	26.30 k	113.10 k	-76.7%
Total calls	42.30 k	212.10 k	-80.1%
Total put/call ratio	0.6	0.5	+16.6%

Largest owners	Shares	Value	Change
Adimab	26.69 mm	$82.47 mm	0.0%
FMR	15.09 mm	$47.24 mm	-0.9%
Mithril Ii	11.24 mm	$0.00	0.0%
M28 Capital Management	9.25 mm	$28.95 mm	+44.5%
GV 2019	5.68 mm	$0.00	0.0%
Orbimed Advisors	5.27 mm	$16.50 mm	+4.2%
Polaris Venture Partners V	4.80 mm	$14.83 mm	0.0%
Vanguard	3.82 mm	$11.96 mm	+15.7%
Slate Path Capital	3.74 mm	$11.69 mm	0.0%
BLK Blackrock	3.48 mm	$10.89 mm	+12.3%

Largest transactions	Shares	Bought/sold	Change
M28 Capital Management	9.25 mm	+2.85 mm	+44.5%
Rubric Capital Management	0.00	-1.81 mm	EXIT
Artal	0.00	-1.00 mm	EXIT
STT State Street	0.00	-935.15 k	EXIT
Vanguard	3.82 mm	+517.65 k	+15.7%
Millennium Management	496.70 k	+401.20 k	+420.1%
BLK Blackrock	3.48 mm	+381.00 k	+12.3%
Citadel Advisors	46.19 k	-380.33 k	-89.2%
Oasis Management	348.43 k	+348.43 k	NEW
GS Goldman Sachs	140.46 k	-272.10 k	-66.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IVVD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Dec 22	Jeremy Gowler	Stock Option Common Stock	Grant	Acquire A	No	No	1.62	625,000	1.01 mm	625,000
14 Dec 22	David Hering	Stock Option Common Stock	Grant	Acquire A	No	No	1.73	900,000	1.56 mm	900,000
14 Dec 22	David Hering	Stock Option Common Stock	Grant	Acquire A	No	No	1.73	700,000	1.21 mm	700,000
14 Dec 22	Peter Schmidt	Stock Option Common Stock	Grant	Acquire A	No	No	1.73	200,000	346.00 k	200,000
14 Dec 22	Jill Andersen	Stock Option Common Stock	Grant	Acquire A	No	No	1.73	300,000	519.00 k	300,000